At Keros, our mission is to innovate therapies
that have the potential to shift the treatment
paradigm for a wide range of patients with
disorders that are linked to dysfunctional
signaling of the transforming growth
factor-beta (TGF-ß) family of proteins.

Learn More

News

  • Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

    March 14, 2024
    Read More
  • Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

    March 5, 2024
    Read More
  • Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

    February 28, 2024
    Read More

Our Therapeutic
Areas of Focus

Female Keros Therapeutics scientist in a lab inspecting a vial of blue liquid

Advancing Novel Therapeutics With a Focus on Cellular Growth & Repair

The transforming growth factor-beta (TGF-β) superfamily is a group of regulatory proteins that is key to the growth, repair and maintenance of blood cells and a number of tissues. Leveraging our deep expertise in TGF-β science, we are focused on developing and commercializing novel therapeutics with the ability to modulate TGF-β signaling and unlock potentially disease-modifying benefits for patients in need.

Learn More

Working at Keros is More Than
A Job - It's A Mission

What Drives Us

Two female Keros Therapeutics employees having a discussion at a high top table

We take our mission personally.

Smiling female scientist in lab inspecting a vial closely

We love our work.

Looking over the shouldrer of a malr Keros Therapeutics scientist testing a sample in a lab

It’s about the science.

Keros employees collaborating on a white board

We invest in our people.

Join Us

Career Opportunities